Placebo News and Research

RSS

AcelRx commences third ARX-01 Phase 3 study in post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced dosing of the first patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia (PCA) system.

24 Aug 2012

Fizzy tablet is best method to receive fentanyl for cancer pain

Results of a mixed treatment comparison show that fentanyl in the form of an effervescent buccal tablet can better relieve the intensity of breakthrough cancer pain in the first 60 minutes after dosing compared with other fentanyl formulations.

23 Aug 2012

CIRT to determine whether methotrexate can reduce heart attacks, strokes and CVD deaths

An international multi-site trial has launched to determine whether a common anti-inflammatory drug can reduce heart attacks, strokes, and deaths due to cardiovascular disease in people at high risk for them. This study is being supported by the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health.

22 Aug 2012

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has initiated dosing in a multicenter (USA), randomized, placebo and active comparator controlled Phase 2b study that will enroll approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% - 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea.

22 Aug 2012

Tips for menopause symptom relief

An estimated 6,000 women in the U.S. reach menopause every day (about two million annually).The most common menopausal complaints include hot flashes, sleep disturbances, anxiety, poor mood, and physical and mental exhaustion. Hot flashes affect 80 percent of peri- or postmenopausal women, with 30 percent reporting hot flashes severe enough to seriously affect their quality of life.

21 Aug 2012

DPT Labs, Imprimis sign agreement to commence work on Impracor clinical supplies

Imprimis Pharmaceuticals, Inc., a specialty pharmaceutical company developing non-invasive, topically delivered products, announced that it has signed an agreement with DPT Labs to commence work on supplying Imprimis with quantities of its active topical anti-inflammatory drug, Impracor, for currently planned Phase 3 clinical trials.

21 Aug 2012

Enzalutamide extends castration-resistant prostate cancer survival

Enzalutamide treatment significantly improves survival in men with castration-resistant prostate cancer, demonstrate phase III trial results published in TheNew England Journal of Medicine.

20 Aug 2012

Physiotherapy beneficial for Parkinson’s patients

Results from a systematic review and meta-analysis published in the BMJ suggest that physiotherapy interventions benefit Parkinson’s disease (PD) patients, at least in the short term.

20 Aug 2012

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial.

20 Aug 2012

FibeBiotics aims to prove benefits of polysaccharides in clinical trials

Staying healthy requires constantly stimulating the immune system. Ingesting non-digestible fibres such as polysaccharides is thought to help. Yet companies including such ingredients in their food products cannot claim that they boost the immune system. At least, not until they have been scientifically tested and proven in clinical trials. Only then, would the European Food Safety Agency (EFSA) allow such health claims.

18 Aug 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Promising new treatment for bronchiectasis

Researchers have identified a promising new treatment for non-cystic fibrosis bronchiectasis, a long-term lung disorder which causes persistent coughing and breathlessness. The results, published in The Lancet, could represent an important advance in the treatment of this debilitating disease, for which very few evidence-based treatments are currently available.

17 Aug 2012

Mepolizumab almost halves exacerbations in severe asthma patients

The largest study of patients with severe asthma to date, published in The Lancet special issue on respiratory medicine, shows that those treated with the monoclonal antibody mepolizumab experienced an almost 50% reduction in severe exacerbations, emergency room visits, and hospitalisations compared with patients given placebo.

17 Aug 2012

Montelukast improves respiratory disturbance and adenoid size in children with OSA

Ben-Gurion University of the Negev (BGU) researchers revealed that a majority of children suffering from Obstructive Sleep Apnea (OSA) treated with montelukast, a drug approved for asthma or hay fever, showed significant improvement in respiratory disturbance and adenoid size, according to a new study published in Pediatrics Journal.

17 Aug 2012

Enzalutamide drug extends survival in people with advanced prostate cancer

Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.

17 Aug 2012

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

17 Aug 2012

Tofacitinib shows promise in active ulcerative colitis

Tofacitinib can induce a clinical response in the majority of patients with moderate to severe, active ulcerative colitis, a placebo-controlled trial has shown.

16 Aug 2012

Enzalutamide drug can extend life and improve QOL in men with advanced prostate cancer

The head of one of the UK's leading cancer research organisations has hailed a golden age in prostate cancer drug discovery as for the fourth time in two years results are published finding a new drug can significantly extend life.

16 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Genocea commences GEN-003 Phase 1/2a study in moderate-to-severe HSV-2 infection

Genocea Biosciences announced today that it has initiated a Phase 1/2a clinical study with its lead candidate, GEN-003. GEN-003 is an investigational vaccine designed to stimulate T cell and B cell immune responses to potentially reduce the frequency and severity of clinical outbreaks associated with moderate-to-severe Herpes Simplex Virus type 2 (HSV-2) infection.

16 Aug 2012

Placebo News and Research

AcelRx commences third ARX-01 Phase 3 study in post-operative pain

Fizzy tablet is best method to receive fentanyl for cancer pain

CIRT to determine whether methotrexate can reduce heart attacks, strokes and CVD deaths

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

Tips for menopause symptom relief

DPT Labs, Imprimis sign agreement to commence work on Impracor clinical supplies

Enzalutamide extends castration-resistant prostate cancer survival

Physiotherapy beneficial for Parkinson’s patients

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

FibeBiotics aims to prove benefits of polysaccharides in clinical trials

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Promising new treatment for bronchiectasis

Mepolizumab almost halves exacerbations in severe asthma patients

Montelukast improves respiratory disturbance and adenoid size in children with OSA

Enzalutamide drug extends survival in people with advanced prostate cancer

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Tofacitinib shows promise in active ulcerative colitis

Enzalutamide drug can extend life and improve QOL in men with advanced prostate cancer

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Genocea commences GEN-003 Phase 1/2a study in moderate-to-severe HSV-2 infection

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News